Actinium Engages Dr. Roland Turck, Former President, Global Specialty Medicine, Bayer Healthcare as Board Advisor Feb 4, 2015
Actinium to Participate in the Canaccord Genuity Rare Disease and Biopharma One-on-One Day on February 3rd Jan 28, 2015
Actinium Submits CMC Meeting Request to FDA for Iomab-B to Support IND Filing and Anticipated Commencement of Phase 3 Trial in Mid-2015 Jan 20, 2015
Actinium's Scientific Advisory Board Endorses and Supports the Iomab-B Phase 3 Clinical Trial Development Program Dec 9, 2014
Experts in Leukemia Treatment Support Ongoing Phase 1/2 Study of Actinium's Actimab-A, a Low Intensity Therapy for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Ages 60 and Older Dec 8, 2014
Actinium Receives Orphan-Drug Designation From FDA for Actimab-A in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients Dec 1, 2014
